Clinical trials: Real-world Study, open to volunteers
Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT)
Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice
Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by…
- Conditions
- Basal Cell Carcinoma of Skin, Optical Coherence Tomography (OCT), Neoplasms, Neoplasms, Basal Cell
- Trial name
- RELI (NCT07501780)
- Where
- Netherlands
- Volunteers
- 297 people
- Sponsor
- Maastricht University Medical Center
This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women in Real World
Community Study to Increase Mammogram Screening Among Overdue Women
Breast cancer is the most common cancer among women in Singapore, and regular mammogram screening can detect breast cancer early when treatment is more effective.
- Trial name
- IMPLEMENT (NCT07832396)
- Testing
- Evidence-based behavioural intervention
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Thyroid Diseases, Thyroid Neoplasms
Thyroid Health Outcomes Registry for Surgery
THORS is a single-center ambidirectional observational cohort study conducted at Moscow Multidisciplinary Clinical Center "Kommunarka".
- Conditions
- Thyroid Diseases, Thyroid Neoplasms, Thyroid Cancer, Thyroid Nodules
- Trial name
- THORS (NCT07812779)
- Volunteers
- 3,000 people
- Sponsor
- Pirogov Russian National Research Medical University
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in…
- Trial name
- UmbREALung (NCT06726720)
- Where
- 70 sites in France, Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
NSCLC Stage IV, PD-L1 Gene Mutation
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell…
- Conditions
- NSCLC Stage IV, PD-L1 Gene Mutation, Atezolizumab, Real World Study
- Trial name
- NCT07279402
- Where
- 25 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Antalya Training and Research Hospital
Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)
Validation of RCC Predicting Model With Emulated-target Trial
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Tumor Thrombus, Prognosis
- Trial name
- RCCETT (NCT07117227)
- Testing
- Model-guided adjuvant treatment, No adjuvant treatment
- Where
- China
- Volunteers
- 4,700 people
- Sponsor
- Peking University Third Hospital
Non-Small Cell Lung Cancer, ALK
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy.
- Conditions
- Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib
- Trial name
- SAILOR (NCT07374614)
- Testing
- Iruplinalkib tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Shenzhen Hospital
Cardiovascular Risk Factors, Menopausal Women
CARAMEL: Retrospective Study for Personalized Risk Assessment of Cardiovascular Disease in Menopausal and Perimenopausal Women Using Real World Data
This retrospective observational study, part of the EU-funded CARAMEL project, aims to develop and validate personalized cardiovascular disease (CVD) risk assessment models specifically designed for menopausal and perimenopausal…
- Conditions
- Cardiovascular Risk Factors, Menopausal Women, Perimenopausal Women, Real World Data
- Trial name
- CARAMEL RS (NCT06999317)
- Volunteers
- 1,500,000 people
- Sponsor
- Hospital Universitario Virgen Macarena
ARDS (Acute Respiratory Distress Syndrome), Real World Study
A Real World Study of Respiratory Critical Disease.
Acute Respiratory Distress Syndrome (ARDS) is a form of acute diffuse lung injury caused by various etiologies, which rapidly progresses to acute respiratory failure.
- Trial name
- NCT07165717
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ming Zhong
Healthy, Real World Data
Clinical and Radiographic Outcomes of the JointMedica Custom-Made Resurfacing Device
The Custom Resurfacing (CR) Implants are indicated for use for the reduction or relief of pain and/or improved hip function all skeletally mature patients where a total joint replacement is indicated, and where there is no other…
- Conditions
- Healthy, Real World Data, Safety and Effectiveness, Patient Reported Outcome (PRO)
- Trial name
- NCT07094139
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- JointMedica Inc.
Healthy, Real World Data
Clinical and Radiographic Outcomes of the JointMedica Polymotion Resurfacing (PHR) Device
The goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the…
- Conditions
- Healthy, Real World Data, Safety and Effectiveness, Patient Reported Outcome (PRO)
- Trial name
- NCT07080671
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- JointMedica Inc.
Hepatocellular Carcinoma (HCC), Real World Study
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
In recent years, immunotherapy represented by PD-1/PD-L1 inhibitors has continuously brought breakthroughs in the treatment of hepatocellular carcinoma and has gradually become the cornerstone of advanced liver cancer treatment.
- Trial name
- NCT07078292
- Volunteers
- 400 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Real-world Study
AI-Assisted Medical Decision-Making
The study builds and applies an AI model to help doctors predict patient diagnoses and outcomes, such as survival or hospital stay.
- Trial name
- NCT06846229
- Testing
- AI-associated strategy
- Where
- 2 sites in China
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- The Eye Hospital of Wenzhou Medical University
ALK-positive Non-small Cell Lung Cancer, Real World Study
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI…
- Trial name
- NCT06361589
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Breast Cancer, Real-world Study
A Real-world Study of Inetetamab for First-line Treatment of MBC
This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2…
- Trial name
- NCT05980208
- Testing
- Inetetamab
- Volunteers
- 150 people
- Sponsor
- Hunan Cancer Hospital